Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30103264 | 0.92 | MDM2 (0.49) | MDM2ALOX12PSDMAPTKDM4E | |
| SCHEMBL23958215 | 0.92 | MDM2 (0.49) | MDM2ALOX12PSDMAPTKDM4E | |
| SCHEMBL24110995 | 0.87 | ALOX12 (0.57) | MDM2ALOX12PSDMAPTG6PD | |
| SCHEMBL24111074 | 0.87 | ALOX12 (0.45) | MDM2ALOX12PSDMAPTPDE7A | |
| SCHEMBL23958345 | 0.86 | G6PD (0.53) | ALOX12SMN1; SMN2ALDH1A1G6PD | |
| SCHEMBL23958227 | 0.86 | ALOX12 (0.46) | MDM2ALOX12PSDMAPTALDH1A1 | |
| SCHEMBL23065136 | 0.86 | MDM2 (0.55) | MDM2ALOX12PSDMAPTKDM4E | |
| SCHEMBL29623220 | 0.86 | MDM2 (0.55) | MDM2ALOX12PSDMAPTKDM4E | |
| SCHEMBL24111000 | 0.85 | ALOX12 (0.49) | MDM2ALOX12PSDMAPTG6PD | |
| SCHEMBL24110973 | 0.84 | ALOX12 (0.47) | MDM2ALOX12PSDMAPTG6PD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
| WO-2021215537-A1 | 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | CRKL, CLIC4, CLIC1 | MDM2 4089/4885ALOX12 3240/4885PSD 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.